Levetiracetam Stadagen

Levetiracetam, the active ingredient in Levetiracetam Stadagen, is an anticonvulsant presented as an oral tablet for oral use. It is employed to control partial, generalized tonic‑clonic and myoclonic seizures in patients diagnosed with epilepsy. The medication is indicated for individuals of various ages who require seizure management as part of a comprehensive treatment plan.

GNH USA supplies Levetiracetam Stadagen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Levetiracetam is an anticonvulsant indicated for several seizure disorders that affect the central nervous system. - Partial seizures: reduces frequency of focal onset seizures. - Generalized tonic‑clonic seizures: helps control convulsive episodes. - Myoclonic seizures: decreases occurrence of rapid muscle jerks.

Levetiracetam may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness - Fatigue - Somnolence - Headache - Nausea

Serious or Rare Side Effects: - Severe allergic reactions (e.g., rash, Stevens‑Johnson syndrome) - Mood alterations such as depression or suicidal thoughts - Blood disorders including thrombocytopenia - Multi‑organ hypersensitivity reactions

When prescribing levetiracetam, clinicians should consider several safety precautions. - Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes and use caution. - Psychiatric symptoms: observe for mood changes, depression, or aggression. - Concomitant CNS depressants: may increase sedation; monitor patient response. - Pregnancy: limited data; evaluate risk‑benefit before use. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Levetiracetam has a relatively low interaction profile, but certain drug combinations require attention.

Major Interactions (Avoid): - Strong enzyme inducers (e.g., carbamazepine, phenytoin, phenobarbital): may lower levetiracetam plasma concentrations. - Alcohol or other CNS depressants: can enhance sedative effects.

Moderate Interactions (Monitor Closely): - Renally cleared drugs (e.g., digoxin, certain antibiotics): monitor therapeutic levels. - Antidepressants (e.g., SSRIs, SNRIs): watch for increased risk of mood changes. - Immunosuppressants (e.g., tacrolimus, cyclosporine): may require concentration monitoring.